Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 4/20 | 0.42 |
| ▸ | HRH2 | P25021 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | KDM1A | O60341 | 3/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095012 | 0.90 | ALDH1A1 (0.53) | ALDH1A1HRH1HRH2POLBLMNA | |
| SCHEMBL6096140 | 0.86 | KCNA5 (0.52) | ALDH1A1HRH1HRH2POLBLMNA | |
| SCHEMBL6741288 | 0.83 | ALDH1A1 (0.51) | ALDH1A1HRH1HRH2POLBLMNA | |
| SCHEMBL6093377 | 0.81 | KCNH2 (0.43) | ALDH1A1TRPV4HRH1HRH2KCNH2 | |
| SCHEMBL6095730 | 0.81 | CHRNA7 (0.41) | TRPV4HRH1HRH2POLBKCNH2 | |
| SCHEMBL7098157 | 0.81 | KCNH2 (0.43) | ALDH1A1TRPV4HRH1HRH2KCNH2 | |
| SCHEMBL5965949 | 0.80 | ALDH1A1 (0.52) | ALDH1A1HRH1HRH2POLBLMNA | |
| SCHEMBL6199933 | 0.79 | HRH2 (0.43) | ALDH1A1HRH1HRH2POLBLMNA | |
| SCHEMBL6093806 | 0.79 | CHRNA7 (0.41) | TRPV4HRH1HRH2KCNH2HRH3 | |
| SCHEMBL6096127 | 0.78 | MGLL (0.47) | TRPV4HRH1HRH2KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144914-B2 | 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1360187-B1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, CACNA1E | ALDH1A1 214/4885TRPV4 625/4885HRH1 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.